Exciting Updates on Lifiravant for NSCLC and Enhanced Survival Outcomes Presented at WCLC 2026 #United_States #NSCLC #Librofaz #Lifiravant #Raritan,_New_Jersey

IRAK1 coordinates #Chemoresistance and #ImmuneEvasion in #NSCLC by regulating ABCB1/ABCC1 and LXRα–ABCA1 signaling, while its inhibition restores cisplatin sensitivity and enhances T-cell-mediated tumor killing.

#STTT #OpenAccess: doi.org/10.1038/s413...

DESTINY-Lung04: #Enhertu batte chemio+pembro in 1L #NSCLC HER2+ • PFS: 14,3 vs 8,3m • ORR: 70% vs 44,5% • OS: 29,3 vs 33,1m

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #notizie #media #TumoreAlPolmone

Ipilimumab/nivolumab plus local consolidation therapy shortens survival in stage IV #NSCLC

Median OS for nivolumab/ipilimumab plus local consolidative therapy was 43.2 months versus 52.8 months without local consolidation therapy #WCLC26

Read: https://bit.ly/4y0cVWt

Updated findings from TRUST-I & TRUST-II were presented in a poster at #WCLC26 🫁

Taletrectinib has shown durable ORRs & a manageable safety profile in patients with ROS1-positive #NSCLC, regardless of ROS1 fusion partners or prior chemo exposure.

Read: https://bit.ly/4y0b18h

DESTINY-Lung04: #Enhertu schlägt Chemo+Pembro in 1L HER2+ #NSCLC
• PFS: 14,3 vs 8,3M
• ORR: 70% vs 44,5%
• OS: 29,3 vs 33,1M

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #Nachrichten #Medien #Lungenkrebs

📣 New Podcast! "Communication and Catharsis, LuAnne Sirdiak, GRACE Clinical Trials Storytelling 2026 #4.1" on @Spreaker #cancer #catharsis #clinical #communication #grace #life #lung #nsclc #sclc #trials #writing

Elaine Yang @yaleschoolofmed.bsky.social presented research during a poster session yesterday at #WCLC in Seoul: "CT-Detected Residual Thymic Tissue Predicts Pathologic Complete Response to Neoadjuvant Therapy in Locally Advanced #NSCLC."
cattendee.abstractsonline.com/meeting/2148...

Dr. VIctor Lee presented a mini-oral session yesterday at #WCLC in Seoul: "ATRX Mutations Are Enriched in Female #NSCLC and Associated With Higher Tumor Mutational Burden."
cattendee.abstractsonline.com/meeting/2148...
@iaslc.bsky.social

New Approval for Librofaz®: Boosting Convenience in Lung Cancer Treatment #Japan #Johnson_&_Johnson #Tokyo #NSCLC #Librofaz®

Phase 3 REZILIENT3 trial results presented at #WCLC2026:

Adding the TKI zipalertinib to 1L chemotherapy improves outcomes in EGFR ex20ins #NSCLC:
• Median PFS: 14.5 vs 8.5 mos
• ORR: 65.0% vs 40.3%
• Median DOR: 14.2 vs 9.9 mos

Full Article: https://bit.ly/46pC3Kk

Ph3 DESTINY-Lung04: #Enhertu erzielt 14,3 Mo. mPFS vs. 8,3 Mo. mit #Pembrolizumab + Chemo bei 1L HER2-mutiertem #NSCLC (37% geringeres Risiko Progress/Tod).
www.ipharmacenter.com/post/iaslc-2...
#WCLC2026 #WCLC26

‼️ Adding amivantamab to chemo improves OS in #NSCLC who have EGRF ex20ins

OS and PFS improved, as well as prolonged time to worsening of symptoms compared w/ chemo alone.

Presented by Chul Kim, MD, at the #WCLC26!

Full Article: https://bit.ly/4dD6Hn8

The EA5221/ACHIEVE clinical study is testing two different treatment approaches for older adults with advanced non-small cell #LungCancer. Learn more: https://bit.ly/ea5221-achieve #NSCLC #LCSM

The PALOMA-2 trial presented by Misako Nagasaka at #WCLC26 found amivantamab plus lazertinib had clinically meaningful and durable antitumor efficacy for #NSCLC 🫁

Dr Nagasaka spoke with us about the PALOMA-2 trial; see the data and read the article here🔽 https://bit.ly/4Ajvt5K

🆕 NEW from #WCLC26! The phase 3 ADAURA trial found:

Patients with stage II-IIIA of EGFR-mutated, early-stage #NSCLC, the 8-year OS was 74% in the osimertinib arm & 58% in the placebo arm. @IASLC

Read more data from the study here: https://bit.ly/4cMq78T

In the Phase 3 IMpower030 trial presented at #WCLC26, perioperative atezolizumab + chemo more than doubled median EFS in resectable stage IIB–IIIB #NSCLC (62.8 vs 34.9 months; HR 0.77). However, the trial missed its primary endpoint.

Link to the article: https://bit.ly/4xQRIhB

At #WCLC26, @danafarber.bsky.social's Dr. Julia Rotow presented primary results from DESTINY-Lung04, the first Phase 3 trial to show a benefit for a HER2-directed therapy over standard chemoimmunotherapy as first-line treatment for HER2-mutant #NSCLC.

➡️bit.ly/4h4SIYu

Zipalertinib Combined with Chemotherapy Enhances Survival Rates in NSCLC Patients #South_Korea #Seoul #NSCLC #Chemotherapy #Zipalertinib

Primary analysis of the Phase 2 MDT-BRIDGE study presented at WCLC 2026 shows encouraging outcomes for perioperative durvalumab + chemotherapy in stage IIB–IIIB #NSCLC 🫁

Presented by Dr Martin Reck at #WCLC2026 @iaslc.bsky.social

Read the article: https://bit.ly/4cKEb2H